Challenges in oral therapy for erectile dysfunction

Journal of Andrology

Volumn 23, Issue 6, 2002, Pages 729-736

  Seftel, Allen D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL; YOHIMBINE;

COLOR VISION DEFECT; DISEASE SEVERITY; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; FUNCTIONAL ANATOMY; HEADACHE; HUMAN; MALE; NAUSEA; NOSE CONGESTION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHINITIS; VASODILATATION; VERTIGO;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; DOPAMINE AGONISTS; HUMANS; IMPOTENCE; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS;

EID: 0036868516     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. American Association of Retired Persons/Modern Maturity Sexuality Study, 1999. Available at: http://research.aarp.org/health/mmsexsurvey. html. Accessed March 11, 2002.
2. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458-465.
3. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56.
4. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164-2171.
5. Blander DS, Sanchez-Ortiz RF, Wein AJ, Broderick GA. Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res. 2000;12:165-168.
6. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
7. Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: a novel player in the regulation of penile erection. Int J Impot Res. 2001a;13:67-72.
8. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001b;7:119-122.
9. Cooke JP. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol. 1997;20(suppl 2):1145-1151.
10. Dai Y, Pollock DM, Lewis RL, Wingard CJ, Stopper VS, Mills TM. Receptor-specific influence of endothelin-1 in the erectile response of the rat. Am J Physiol Regul Integr Comp Physiol. 2000;279:R25-R30.
11. Diederichs W, Stief CG, Lue TF, Tanagho EA. Norepinephrine involvement in penile detumescence. J Urol. 1990;143:1264-1266.
12. Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology. 1999;53:800-805.
13. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol. 2001;166:927-931.
14. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57:1141-1144.
15. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995;22:833-845.
16. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
17. Feng MI, Huang S, Kaptein J, Kaswick J, Aboseif S. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J Urol. 2000;164:1935-1938.
18. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2000;65:1-53.
19. Giuliano F, Montorsi F, Mirone V, Rossi D, Sweeney M for the Sildenafil Multicenter Study Group. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. J Urol. 2000;164:708-711.
20. Goldstein I, Carson C, Rosen R, Islam A. Vasomax for the treatment of male erectile dysfunction. World J Urol. 2001;19:51-56.
21. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.
22. Gonzalez CM, Bervig T, Podlasek C, Huang C-F, McKenna KE, McVary KT. Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina. Int J Impot Res. 1999;11(suppl 1):S9-S14.
23. Hansen-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998;159:1541-1547.
24. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res. 2002;14(suppl 1):S43-S52.
25. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol. 2000;164:1197-1200.
26. Heaton JPW. Apomorphine: an update of clinical trial results. Int J Impot Res. 2000;12(suppl 4):S67-S73.
27. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol. 2001;19:25-31.
28. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun. 1990;170:843-850.
29. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation. 2001;104:864-869.
30. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, Nakano T. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal. 1996;8:575-581.
31. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162:722-725.
32. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114-1118.
33. Klotz T, Sachse R, Heidrich A, Jockenhövel F, Rohde G, Wensing G, Horstmann R, Engelman R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001;19:32-39.
34. Laight DW, Carrier MJ, Änggård EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev. 1999;15:274-282.
35. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544.
36. Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: new insights and more questions. J Urol. 1993;149:1246-1255.
37. Lin C-S, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun. 2000;268:628-635.
38. Madduri SD. After two years, did Viagra live up to its expectations? Missouri Med. 2001;98:243-245.
39. McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston GD. Vasoconstriction to endogenous endothelin-1 is impaired in patients with type II diabetes mellitus. Clin Sci. 2000;99:175-179.
40. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol. 2000;164:1192-1196.
41. McVary KT, Carrier S, Wessells H and the Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624-1632.
42. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999;161:5-11.
43. Mills TM, Chitaley K, Lewis RW. Vasoconstrictors in erectile physiology. Int J Impot Res. 2001;13(suppl 5):S29-S34.
44. Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res. 2000:12(suppl 1):S70-S74.
45. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69-74.
46. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113-120.
47. Moreland RB. Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism. Int J Impot Res. 2000;12(suppl 4):S39-S46.
48. Mulhall JP, Bukofzer S, Edmonds AL, George M and the Apomorphine SL Study Group. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther. 2001;23:1260-1271.
49. NDC Health. Viagra persistency rates: 1998-2000. 2001.
50. Nehra A, Goldstein I, Pabby A; et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156:1320-1329.
51. NIH Consensus Conference. Impotence NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
52. Olsson AM, Persson C-A. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract. 2001;55:171-176.
53. Padma-Nathan H. Challenges and solutions in the treatment of erectile dysfunction, http://www.medscape.com/Medscape/urology/ClinicalUpdate/2001/cu01/ pnt-cu01.html. Accessed November 20, 2001.
54. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC for the IC351 On-Demand Dosing Study Group. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13:2-9.
55. Padma-Nathan H, Steers WD, Wicker PA for the Sildenafil Study Group. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract. 1998;52:375-380.
56. Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. J Urol. 2000;164:958-961.
57. Pfizer Inc. Viagra (sildenafil citrate) tablets: prescribing information. Pfizer Inc; 2000.
58. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002;14(suppl 1):S57-S64.
59. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T and the Vardenafil Study Group. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192-199.
60. Pryor JL, Redmon B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int J Impot Res. 2000;12(suppl 4):S158-S162.
61. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to non-adrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
62. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol. 2001;133:455-458.
63. Rendell MS, Rajfer J, Wicker PA, Smith MD for the Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281:421-426.
64. Rosen R, Goldstein I, Padma-Nathan H. A Process of Care Model: Evaluation and Treatment of Erectile Dysfunction. The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School;1998.
65. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract. 2001;55:115-128.
66. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2000;12(suppl 4):S34-S38.
67. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2002;14(suppl 1):S6-S10.
68. Sáenz de Tejada I, Blanco R, Goldstein I, Azadzoi K, De Las Morenas A, Krane RJ, Cohen RA. Cholinergic neurotransmission in human corpus cavernosum I. Responses of isolated tissue. Am J Physiol. 1988;254(3 part 2):H459-H467.
69. Sáenz de Tejada I, Carson MP, de las Morenas A, Goldstein I, Traish AM. Endothelin: localization, synthesis, activity, and receptor types in human penile corpus cavernosum. Am J Physiol. 1991;261:H1078-1085.
70. Sáenz de Tejada I, Kim NN, Goldstein I, Traish AM. Regulation of presynaptic alpha adrenergic activity in the corpus cavernosum. Int J Impot Res. 2000;12(suppl 1):S20-S25.
71. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52:848-852.
72. Stanarius A, Uckert S, Machtens SA, Stief CG, Wolf G, Jonas U. Immunocytochemical distribution of nitric oxide synthase in the human corpus cavernosum: an electron microscopical study using the tyramide signal amplification technique. Urol Res. 2001;29:168-172.
73. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J Urol. 1997;158:1966-1972.
74. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res. 1999;43:658-665.
75. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem. 1958;232:1077-1091.
76. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous muscle. World J Urol. 1997;15:32-35.
77. Taub HC, Lerner SE, Melman A, Christ GJ. Relationship between contraction and relaxation in human and rabbit corpus cavernosum. Urology. 1993;42:698-704.
78. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res. 2000;12(suppl 1):S48-S63.
79. Traish AM, Netsuwan N, Daley J, Padma-Nathan H, Goldstein I, Sáenz de Tejada I. A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol. 1995;153:222-227.
80. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999;54:1073-1077.
81. Wespes E. Erectile dysfunction in the ageing man. Curr Opin Urol. 2000;10:625-628.
82. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology. 1999;53:775-778.
83. Zesiewicz TA, Hauser RA, Helal M. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Neurology. 1999;52(suppl 2):305-308.